Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI response correctly labeled dizziness and somnolence as adverse effects and acknowledged driving impairment risk; however, it largely failed to align with label content on blood pressure-related interactions (hypotension, orthostatic hypotension, antihypertensive interactions), giving numerous unsupported or off-label claims. Overall, the alignment is partial with notable omissions.
Category Scores
Accurate Statements
Lyrica (pregabalin) can cause dizziness.
5.5, 6
Dizziness and somnolence from pregabalin can interfere with day-to-day functioning.
5.5, 6
Patients should avoid driving or risky activities if they feel dizzy or drowsy.
5.5
Patients should talk to their clinician if they get dizziness, faintness, or unusual fatigue.
5.5
Unsupported Statements
Lyrica (pregabalin) can cause low blood pressure (hypotension).
Not supported by the provided label text.
Lyrica (pregabalin) can cause balance problems.
Not supported by the provided label text.
Pregabalin can affect how well blood pressure medications work.
Not supported by the provided label text.
Pregabalin can increase the likelihood of falls in people who are already prone to dizziness from antihypertensives.
Not supported by the provided label text.
The combination of pregabalin and antihypertensives can have an additive effect on lowering blood pressure.
Not supported by the provided label text.
The combination can raise the risk of symptomatic hypotension (lightheadedness, fainting).
Not supported by the provided label text.
The risk of additive hypotension is especially noticeable when starting pregabalin, when the dose is increased, or in older adults.
Not supported by the provided label text.
Dizziness from pregabalin can become more prominent when a blood pressure medicine is already lowering blood pressure, leading to dose adjustments or missed medicines.
Not supported by the provided label text.
Dose adjustments or missed medicines can worsen blood pressure control.
Not supported by the provided label text.
The interaction risk is most relevant for blood pressure therapies that already have a higher chance of causing low blood pressure or dizziness.
Not supported by the provided label text.
Orthostatic hypotension is more common with some antihypertensive classes.
Not supported by the provided label text.
The higher-risk scenario is when both pregabalin and an antihypertensive contribute to low blood pressure symptoms, regardless of the antihypertensive class.
Not supported by the provided label text.
If pregabalin plus an antihypertensive causes symptomatic hypotension, patients may experience lightheadedness or seeing stars, especially when standing up.
Not supported by the provided label text.
Clinicians may adjust either the pregabalin dose or the blood pressure regimen to restore stable blood pressure.
Not supported by the provided label text.
The timing pattern most likely to matter is after starting pregabalin.
Not supported by the provided label text.
The timing pattern most likely to matter is after increasing the pregabalin dose.
Not supported by the provided label text.
The timing pattern most likely to matter is during dehydration, illness, or hot weather (when blood pressure medicines can have a stronger effect).
Not supported by the provided label text.
In these situations, low blood pressure is more likely from the combination.
Not supported by the provided label text.
Patients taking both pregabalin and blood pressure medication are usually advised to rise slowly from sitting or lying down.
Not supported by the provided label text.
Patients should monitor blood pressure (and note symptoms), particularly during dose changes.
Not supported by the provided label text.
Contradictions
Important Omissions
No label-provided discussion of antihypertensive interaction risk (hypotension/orthostatic hypotension), monitoring recommendations for blood pressure, or guidance on adjusting pregabalin dose relative to antihypertensive therapy.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Most addressed claims concern dizziness/somnolence with modest functional impact; however, several BP-related interactions are not supported, representing potential safety information gaps.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about blood pressure interactions and antihypertensive coadministration are not supported by the provided label excerpt; provide alignment with label on BP-related safety and monitoring.
Suggested Improvement
Restrict statements to label-supported BP safety (dizziness/somnolence with pregabalin, driving impairment) and avoid or clearly label as unvalidated (BP interactions, dose adjustment guidance with antihypertensives). Include monitoring and counseling language consistent with Warning 5.5 and patient counseling materials.